Langley, R. E., Cafferty, F. H., Alhasso, A. A., Rosen, S. D., Sundaram, S. K., Freeman, S. C., . . . Abel, P. D. (2013). Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: The randomised, phase 2 MRC PATCH trial (PR09). Lancet Pub. Group.
Chicago Style CitationLangley, Ruth E., et al. Cardiovascular Outcomes in Patients With Locally Advanced and Metastatic Prostate Cancer Treated With Luteinising-hormone-releasing-hormone Agonists or Transdermal Oestrogen: The Randomised, Phase 2 MRC PATCH Trial (PR09). Lancet Pub. Group, 2013.
Cita MLALangley, Ruth E., et al. Cardiovascular Outcomes in Patients With Locally Advanced and Metastatic Prostate Cancer Treated With Luteinising-hormone-releasing-hormone Agonists or Transdermal Oestrogen: The Randomised, Phase 2 MRC PATCH Trial (PR09). Lancet Pub. Group, 2013.